Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis
2021; Lippincott Williams & Wilkins; Volume: 145; Issue: 1 Linguagem: Inglês
10.1161/circulationaha.121.057538
ISSN1524-4539
AutoresJustin L. Grodin, Larry D. Anderson, Ankit Kansagra,
Tópico(s)Parathyroid Disorders and Treatments
Resumoight chain cardiac amyloidosis (AL-CA) is a devastating disease caused by a buildup of abnormal, misfolded light chain aggregates in the myocardium.When untreated, AL-CA leads to progressive heart failure and premature death.The long-term prognosis of AL-CA is dependent on the disease stage at diagnosis and then the response to treatment.Median survival of advanced stage AL-CA at diagnosis may approximate 6 months. 1 These sobering metrics have served to motivate the detection of AL-CA in earlier stages and the continued advancements of treatment for AL-CA.
Referência(s)